Quick View
| Metric | Current Period | Previous Period | YoY |
|---|---|---|---|
| Revenue | - | - | - |
| Operating Income | - | - | +105.2% |
| Ordinary Income | ¥3.54B | ¥4.94B | −28.3% |
| Net Income | ¥2.20B | ¥3.19B | −31.0% |
| ROE | 7.6% | 11.4% | - |
Executive Summary
Despite higher revenue, earnings declined due to deteriorating profitability in the core non-life insurance business. Consolidated ordinary revenue increased to ¥73.85B (+9.1% YoY), while ordinary income fell significantly to ¥3.54B (¥4.94B in the previous period, YoY -28.3%) and net income declined to ¥2.20B (¥3.19B in the previous period, YoY -31.0%). The primary factors were the decline in the profit margin of the core non-life insurance business (profit margin: 9.2%→7.3%) and the widening loss in the veterinary hospital operations business (¥-0.03B in the previous period→¥-0.72B).
Factors Affecting Performance
【Revenue】Consolidated ordinary revenue increased 9.1% YoY to ¥73.85B. The core non-life insurance business led revenue growth, generating ¥65.82B (89.1% of total revenue, +8.8% YoY). The health innovation business achieved strong growth at ¥0.57B (+65.6% YoY), although its scale remains small. The veterinary hospital operations business also expanded to ¥2.40B (+10.7% YoY), while growth in the internet services business for pets slowed to ¥2.27B (+1.3% YoY).
【Profit and Loss】Ordinary income declined to ¥3.54B (YoY -28.3%), while net income fell to ¥2.20B (YoY -31.0%). Segment income in the non-life insurance business was ¥4.80B, down 14.4% YoY, and its profit margin declined from 9.2% to 7.3%. The loss ratio of 58.1% was favorable, but the expense ratio of 32.3% weighed on the profit margin. Despite higher revenue, the veterinary hospital operations business recorded a loss of ¥0.72B (¥-0.03B in the previous period), reflecting upfront investments in locations and research. Extraordinary losses of ¥0.33B, including impairment losses of ¥0.23B, also reduced profit before tax and widened the gap between ordinary income and net income. In conclusion, the company reported higher revenue but lower earnings.
Segment Analysis
The non-life insurance business generated revenue of ¥65.82B (89.1% of total revenue, YoY +8.8%) and segment income of ¥4.80B (YoY -14.4%, profit margin 7.3%). It remains the core contributor to company-wide earnings, although profitability declined from the previous year. The veterinary hospital operations business recorded revenue of ¥2.40B (YoY +10.7%) and an expanded loss of ¥0.72B (¥-0.03B in the previous year), as upfront costs associated with hospital succession and research investments weighed on results. The internet services business for pets generated revenue of ¥2.27B (YoY +1.3%) and income of ¥0.10B (YoY -56.9%), indicating slower growth. The health innovation business achieved strong revenue growth to ¥0.57B (YoY +65.6%), but recorded a loss of ¥0.31B (¥-0.13B in the previous year), and has not yet reached the investment recovery stage. Other businesses improved, with revenue of ¥2.78B (YoY +13.7%) and a reduced loss of ¥0.30B (¥-0.73B in the previous year), suggesting signs of a recovery in profitability.
Key Financial Indicators
【Profitability】The ordinary income margin declined to 4.8% from 7.3% in the previous period, while the net income margin also fell to 3.0% (4.8% in the previous period). In the non-life insurance business, the loss ratio was 58.1% and the expense ratio was 32.3%, resulting in a combined ratio of 90.4%. Underwriting income was secured, but the expense burden remains a constraint on profitability.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥4.82B, equivalent to 2.19 times net income of ¥2.20B. OCF/EBITDA was also approximately 1.0 times, indicating strong cash backing for earnings.【Investment Efficiency】ROE was 7.6%, while capital expenditures of ¥4.92B reached 4.0 times depreciation and amortization of ¥1.23B, indicating that the company is in an expansion investment phase.【Financial Soundness】The equity ratio remained broadly unchanged at 37.7% (37.9% in the previous period), while bonds were reduced from ¥10.0B in the previous period to ¥5.00B. Interest coverage remained high, and the interest burden was limited.
Cash Flow Analysis
Operating Cash Flow was ¥4.82B, down 24.7% YoY, but reached 2.19 times net income of ¥2.20B, indicating good quality of earnings conversion into cash. Meanwhile, investing cash flow was an outflow of ¥16.67B, largely attributable to the acquisition of short-term investment securities. Capital expenditures also amounted to ¥4.92B, or 4.0 times depreciation and amortization of ¥1.23B. As a result, free cash flow recorded a deficit of ¥11.85B. Financing cash flow was an outflow of ¥1.67B, with the redemption of ¥5.00B in bonds, the acquisition of treasury stock for ¥1.02B, and dividend payments of ¥0.64B serving as sources of cash outflow. Consequently, cash and cash equivalents declined by ¥13.52B to ¥0.91B. The primary causes were a shift of funds into investment assets and debt reduction, rather than a simple deterioration in the underlying business.
Quality of Earnings
Operating Cash Flow reached 2.19 times net income, and the accrual ratio was also in negative territory, indicating strong cash-generation backing for current-period earnings. In terms of underwriting in the non-life insurance business, the loss ratio was 58.1%, the expense ratio was 32.3%, and the combined ratio was 90.4%; underwriting profitability itself remained at a sound level. However, extraordinary losses of ¥0.33B included impairment losses of ¥0.23B, resulting in a temporary downward impact between profit before tax of ¥3.22B and ordinary income of ¥3.54B. The ¥0.31B difference between net income of ¥2.20B and comprehensive income of ¥2.51B was primarily attributable to changes in the valuation difference on available-for-sale securities. Equity-method investment income was modest at ¥-0.05B, and its impact on ordinary items was limited.
Earnings Forecast and Guidance
The company forecasts ordinary income of ¥5.00B for the next period (YoY +41.1% from current-period actual results), EPS of ¥44.43, and a dividend of ¥13.5. The plan anticipates a substantial increase in earnings from current-period actual ordinary income of ¥3.54B and EPS of ¥29.77. Achievement of the forecast will depend on a recovery in the profit margin of the core non-life insurance business and a reduction in losses in peripheral businesses, particularly veterinary hospital operations. The profit margin of the non-life insurance business declined to 7.3% in the current period, making improvement in the expense ratio a key factor in achieving the next-period forecast.
Shareholder Returns
The annual dividend for the current period was ¥9.0 per share, with total dividend payments of ¥0.66B, resulting in a payout ratio of 30.2% based on net income. Including the ¥1.02B acquisition of treasury stock, the Total Return Ratio was approximately 76%, which should be distinguished from the payout ratio based solely on dividends. Operating Cash Flow of ¥4.82B exceeded total dividend payments; however, because free cash flow was in a deficit of ¥11.85B, the funding source for shareholder returns remains partly dependent on trends in investing cash flow. The company forecasts an annual dividend of ¥13.5 for the next period, representing a planned dividend increase of 50.0% from the current-period actual result.
Risk Factors
-
Concentration of earnings in the core non-life insurance business: The non-life insurance business accounts for 89.1% of ordinary revenue, and its profit margin declined from 9.2% to 7.3%. The potential for improvement in the 32.3% expense ratio will be a factor affecting consolidated earnings volatility.
-
Delayed monetization of the veterinary hospital operations business: The business recorded a loss of ¥0.72B on revenue of ¥2.40B, widening from ¥-0.03B in the previous period. Fixed-asset and intangible-asset investments are preceding earnings generation, and delays in recovering these investments could remain a source of recurring losses.
-
Free cash flow deficit accompanying expanded investment: FCF was in a deficit of ¥11.85B, and capital expenditures reached 4.0 times depreciation and amortization. The pace of investment monetization may affect financial flexibility.
Industry Benchmark (For Reference; Compiled by the Company)
No industry benchmark data available
Source: Compiled by the Company
Key Takeaways from the Financial Results
-
Ordinary revenue increased 9.1%, but ordinary income declined 28.3% and net income declined 32.1%, indicating a clear divergence between revenue growth and earnings growth.
-
The combined ratio in the non-life insurance business was 90.4% (loss ratio 58.1%, expense ratio 32.3%), securing underwriting income itself; however, the level of the expense ratio is constraining the profit margin.
-
Operating Cash Flow was 2.19 times net income, indicating strong cash-generation capacity. However, free cash flow was in a deficit of ¥11.85B due to expansion investments, making the progress of investment recovery a key determinant of future capital allocation.
This report is an earnings analysis document automatically generated by AI based on XBRL financial results summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed financial results data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.
---End of Report---